Investors evaluating targeted healthcare exposure often compare thematic and sector-specific exchange-traded funds (ETFs) like IDNA and XBI. These funds do not compete directly but instead offer complementary approaches within biotechnology and life sciences. IDNA emphasizes global companies positioned for long-term growth in genomics, immunology, and bioengineering, while XBI delivers broad access to the U.S. biotechnology industry through an equal-weighted index. The comparison helps investors understand differences in strategy, diversification, costs, and positioning amid ongoing innovation in drug development and personalized medicine.
The iShares Genomics Immunology and Healthcare ETF (IDNA) seeks to track the NYSE FactSet Global Genomics and Immuno Biopharma Index. This rules-based, passive strategy selects developed and emerging market companies that may benefit from advancements in genomics, immunology, and bioengineering. The fund typically holds around 50 securities, with significant allocations to health care. Top holdings often include Moderna Inc. (MRNA), Twist Bioscience Corp. (TWST), and Iovance Biotherapeutics Inc. (IOVA), reflecting concentration in innovative biopharmaceutical names. The expense ratio stands at 0.47%. IDNA maintains nearly 100% exposure to the health care sector and features a global footprint with primary weight in the United States and select developed markets. Rebalancing follows the underlying index methodology.
The SPDR S&P Biotech ETF (XBI) tracks the S&P Biotechnology Select Industry Index using a passive, equal-weighted approach. This methodology assigns roughly equal importance to U.S. biotechnology companies across market capitalizations, resulting in approximately 160 holdings. Top positions typically represent about 2% each, including names such as Twist Bioscience Corp. (TWST), Moderna Inc. (MRNA), and Natera Inc. (NTRA). The expense ratio is 0.35%. XBI allocates nearly all assets to the biotechnology sub-industry within health care and maintains primarily domestic exposure. Quarterly rebalancing supports the equal-weight structure, promoting broader representation across small-, mid-, and large-cap biotech firms.
The biotechnology sector continues to evolve amid advances in gene editing, immunotherapy, and precision medicine. Capital flows into life sciences reflect sustained interest in innovation pipelines, supported by regulatory pathways for novel therapies and potential shifts in interest rate expectations that influence growth-oriented investments. Macroeconomic factors, including research and development spending and clinical trial outcomes, drive sector dynamics. Risks include high development failure rates, patent expirations, and policy changes affecting drug pricing and reimbursement. Both ETFs operate within this environment, where thematic exposure to emerging technologies and broad sector participation respond differently to earnings cycles and capital allocation trends in healthcare.
In recent market cycles, IDNA's thematic focus has led to distinct volatility patterns tied to developments in genomics and immunology companies, while XBI's equal-weighted construction has provided smoother participation across the broader U.S. biotech landscape. Relative positioning highlights IDNA's sensitivity to innovation milestones and global supply chains versus XBI's alignment with domestic sector rotation and earnings breadth. During periods of biotech strength, XBI's diversification across more holdings has supported consistent exposure, whereas IDNA's concentration amplifies outcomes from select high-conviction names. Both funds exhibit elevated volatility compared to broad market benchmarks due to their healthcare emphasis, with differences stemming from geographic scope and weighting methodologies rather than short-term price fluctuations.
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Investors seeking data-driven insights into ETFs like IDNA and XBI can leverage this platform for efficient discovery.
Based on observable structural factors including lower expense ratio, greater number of holdings, and equal-weighted diversification that reduces concentration risk, Tickeron’s AI would currently assign a higher probabilistic preference to XBI for investors seeking broad U.S. biotech exposure. IDNA offers compelling thematic depth in genomics and immunology but carries higher costs and narrower holdings. The assessment weighs cost efficiency, diversification profile, and sector momentum without constituting investment advice.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
The 10-day moving average for IDNA crossed bearishly below the 50-day moving average on November 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IDNA as a result. In 81 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
The Moving Average Convergence Divergence Histogram (MACD) for IDNA turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 44 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 86%.
IDNA moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The RSI Indicator entered the oversold zone -- be on the watch for IDNA's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDNA advanced for three days, in 243 of 283 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
IDNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 167 of 201 cases where IDNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Following a +5.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where XBI advanced for three days, in 295 of 322 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
XBI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XBI as a result. In 82 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for XBI turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 48 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
XBI moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for XBI crossed bearishly below the 50-day moving average on November 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for XBI entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
| IDNA | XBI | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | N/A |
| Stochastic ODDS (%) | 1 day ago 85% | 1 day ago 90% |
| Momentum ODDS (%) | 1 day ago 88% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 86% | 1 day ago 89% |
| TrendWeek ODDS (%) | 1 day ago 88% | 1 day ago 88% |
| TrendMonth ODDS (%) | 1 day ago 89% | 1 day ago 89% |
| Advances ODDS (%) | 12 days ago 86% | 12 days ago 90% |
| Declines ODDS (%) | 1 day ago 87% | 1 day ago 89% |
| BollingerBands ODDS (%) | 1 day ago 89% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 83% | 1 day ago 85% |
A.I.dvisor indicates that over the last year, IDNA has been loosely correlated with FATE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if IDNA jumps, then FATE could also see price increases.
| Ticker / NAME | Correlation To IDNA | 1D Price Change % | ||
|---|---|---|---|---|
| IDNA | 100% | -2.14% | ||
| FATE - IDNA | 57% Loosely correlated | -9.01% | ||
| DNA - IDNA | 56% Loosely correlated | -9.02% | ||
| SANA - IDNA | 51% Loosely correlated | -8.62% | ||
| BNGO - IDNA | 51% Loosely correlated | -7.10% | ||
| ABUS - IDNA | 51% Loosely correlated | -1.23% | ||
More | ||||
A.I.dvisor indicates that over the last year, XBI has been loosely correlated with RCUS. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if XBI jumps, then RCUS could also see price increases.
| Ticker / NAME | Correlation To XBI | 1D Price Change % | ||
|---|---|---|---|---|
| XBI | 100% | -2.73% | ||
| RCUS - XBI | 60% Loosely correlated | -1.01% | ||
| VYGR - XBI | 59% Loosely correlated | -4.97% | ||
| LYEL - XBI | 57% Loosely correlated | +1.62% | ||
| LGND - XBI | 56% Loosely correlated | -0.03% | ||
| MGNX - XBI | 55% Loosely correlated | -1.01% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BNDD | 97.22 | 0.90 | +0.94% |
| Quadratic Deflation ETF (BNDD) | |||
| UNL | 5.47 | 0.03 | +0.55% |
| United States 12 Month Natural Gas Fund LP (UNL) | |||
| SCHJ | 24.24 | 0.08 | +0.33% |
| Schwab 1-5 Year Corporate Bond ETF (SCHJ) | |||
| VYM | 153.87 | -3.23 | -2.06% |
| Vanguard High Dividend Yield Index ETF (VYM) | |||
| BFOR | 21.47 | -0.61 | -2.76% |
| ALPS Barron's 400 ETF (BFOR) | |||